Published in Sci Rep on February 13, 2012
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood (2013) 1.17
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One (2013) 1.14
Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother (2013) 1.13
Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther (2013) 1.09
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov (2016) 1.06
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A (2014) 0.94
Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep (2014) 0.89
Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol (2014) 0.89
Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Mol Ther (2016) 0.85
Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother (2014) 0.84
Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One (2015) 0.82
Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther (2013) 0.82
Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. Vet Sci (2015) 0.76
NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells. Front Immunol (2016) 0.75
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers. Mol Ther (2016) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol (2008) 15.90
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer (2008) 3.23
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther (2007) 2.99
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res (2008) 2.57
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol (2005) 2.44
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res (2008) 2.37
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96
Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol (2006) 1.68
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood (2009) 1.67
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
Biology of IL-21 and the IL-21 receptor. Immunol Rev (2004) 1.56
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol (2006) 1.51
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol (2009) 1.40
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant (2008) 1.37
Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg (2011) 1.36
Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol (2006) 1.36
Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer (2008) 1.33
Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) (2004) 1.15
Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol (2007) 1.12
Comparative oncology today. Vet Clin North Am Small Anim Pract (2007) 1.09
Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell (2007) 1.05
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol (2010) 1.05
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immunother (2010) 1.03
Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc (1997) 1.02
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) (2011) 1.01
Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol (1992) 0.98
Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+ CD3+ count reconstitution is associated with survival. Bone Marrow Transplant (2007) 0.94
Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay. Int J Oncol (2009) 0.90
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res (2005) 0.90
Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother (2009) 0.89
Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res (2004) 0.89
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma (2005) 0.88
Adoptive immunotherapy against kidney targets in dog-leukocyte antigen-identical mixed hematopoietic canine chimeras. Transplantation (2003) 0.87
Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med (2010) 0.86
Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother (2009) 0.86
A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther (2010) 0.85
Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Anticancer Res (2010) 0.84
Expression and function of T cell homing molecules in Hodgkin's lymphoma. Cancer Immunol Immunother (2008) 0.83
Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma (2010) 0.82
Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol (2011) 0.81
Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. Anticancer Res (2010) 0.78
The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Vet Immunol Immunopathol (2006) 0.77
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res (2005) 4.84
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res (2006) 4.06
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation (2010) 3.65
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol (2008) 3.51
A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev (2006) 3.49
The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell (2004) 3.44
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med (2012) 3.39
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 3.13
Extreme diving of beaked whales. J Exp Biol (2006) 2.95
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant (2002) 2.87
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol (2012) 2.76
A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndrome. Am J Obstet Gynecol (2007) 2.73
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res (2008) 2.57
The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway. Nat Struct Mol Biol (2005) 2.55
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res (2004) 2.54
Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med (2004) 2.53
Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr (2005) 2.44
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
Deep-diving foraging behaviour of sperm whales (Physeter macrocephalus). J Anim Ecol (2006) 2.41
The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res (2012) 2.35
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol (2011) 2.29
A transposon and transposase system for human application. Mol Ther (2010) 2.28
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol (2014) 2.26
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 2.25
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood (2002) 2.20
A double-blind randomized controlled clinical trial to assess the effect of Doppler optimized intraoperative fluid management on outcome following radical cystectomy. J Urol (2011) 2.19
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood (2007) 2.16
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer (2009) 2.15
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res (2009) 2.10
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 2.09
Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for diabetes in youth study. Diabetes Care (2006) 2.09
Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr (2006) 2.06
Mapping infant brain myelination with magnetic resonance imaging. J Neurosci (2011) 1.97
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Control of spin precession in a spin-injected field effect transistor. Science (2009) 1.93
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature (2008) 1.91
Ocular biomechanics and biotransport. Annu Rev Biomed Eng (2004) 1.91
Reducing DUI among US college students: results of an environmental prevention trial. Addiction (2005) 1.87
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood (2002) 1.87
Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome. J Clin Invest (2008) 1.86
Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. J Pediatr Surg (2002) 1.84
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res (2009) 1.80
The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res (2008) 1.77
CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis (2002) 1.72
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer (2013) 1.71
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood (2012) 1.69
Edge-based scoring and searching method for identifying condition-responsive protein-protein interaction sub-network. Bioinformatics (2007) 1.69
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol (2006) 1.67
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
The oil spill in ageing Bruch membrane. Br J Ophthalmol (2011) 1.62
The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment. Biol Blood Marrow Transplant (2011) 1.60
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood (2012) 1.58
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood (2005) 1.57
Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis (2013) 1.55
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem (2010) 1.55
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant (2005) 1.55
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. J Immunother (2009) 1.52
Characterising the complexity of medication safety using a human factors approach: an observational study in two intensive care units. BMJ Qual Saf (2013) 1.52
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood (2013) 1.52
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis. Proc Natl Acad Sci U S A (2006) 1.51
Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories. Bioinformatics (2007) 1.50
Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. Arch Pediatr Adolesc Med (2007) 1.49
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res (2005) 1.49
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood (2004) 1.48